BioCentury | Aug 9, 2019
Clinical News

Aug. 9 Clinical Quick Takes: Lexicon's one-year Zynquista follow-up; plus 89bio and TopiVert

...Standing Out in the NASH Crowd" ). TopiVert fails Phase IIb/III dry eye disease study TopiVert...
...SGLT2 - Sodium-glucose cotransporter 2 Sandi Wong, Staff Writer BIO89-100 (TEV-47948) TOP1630 Zynquista, sotagliflozin (SAR439954, lx4211 tablet) 89Bio Ltd. Lexicon Pharmaceuticals Inc. TopiVert Ltd. Non-alcoholic...
BioCentury | Nov 28, 2018
Company News

Management tracks: Abeona, INKEF, Incyte

...COO. Staples was CBO at Artios Pharma Ltd. (Cambridge, U.K.) as well as CBO at TopiVert Ltd....
BioCentury | Mar 10, 2017
Clinical News

TOP1630: Ph I/IIa started

...TopiVert began a U.S. Phase I/IIa trial to evaluate topical TOP1630. TopiVert Ltd. , London, U.K. Product...
...Treat dry eye syndrome Endpoint: Safety Status: Phase I/IIa started Milestone: Phase I/IIa data (2H17) Nora Weintraub TOP1630 TopiVert Ltd....
BioCentury | Oct 17, 2016
Clinical News

rectal TOP1288: Phase IIa started

...once daily for 4 weeks in about 60 patients with moderate to severe disease activity. TopiVert...
...which Johnson & Johnson acquired (see BioCentury, June 7, 2010 & Dec. 12, 2011). TopiVert Ltd....
BioCentury | Mar 28, 2016
Clinical News

TOP1288: Phase I data

...days. Data were presented at the European Crohn’s and Colitis Organization meeting in Amsterdam. Mid-year, TopiVert...
...company also plans to start a Phase I trial evaluating an oral formulation of TOP1288. TopiVert...
...RespiVert Ltd. , which J&J acquired (see BioCentury, June 7, 2010 & Dec. 12, 2011). TopiVert Ltd....
BioCentury | May 25, 2015
Clinical News

TOP1288: Phase I started

...and multiple ascending doses of rectal TOP1288 in healthy volunteers and multiple doses in patients. TopiVert...
...which Johnson & Johnson acquired (see BioCentury, June 7, 2010 & Dec. 12, 2011). TopiVert Ltd....
BioCentury | Jan 16, 2014
Strategy

Biotech kibbutz

...Center Bioceros B.V. Cancer mAb against an undisclosed immune checkpoint regulator to enhance antitumor immunity TopiVert Ltd....
BioCentury | Jan 6, 2014
Financial News

TopiVert completes venture financing

...million) Investors: NeoMed; SV Life Sciences; Imperial Innovations Group; Johnson & Johnson Development Corp. Note: TopiVert...
BioCentury | Dec 12, 2011
Company News

TopiVert, J&J deal

...kinase inhibitors using IP from RespiVert, which was acquired by Johnson & Johnson in 2010. TopiVert...
...inflammatory diseases, while RespiVert will have exclusive rights for other indications. Details were not disclosed. TopiVert Ltd....
BioCentury | Dec 12, 2011
Company News

TopiVert board of directors update

TopiVert Ltd. , London, U.K. Business: Inflammation Appointed: Maina Bhaman, director of Healthcare Investments at Imperial Innovations Group plc WIR Staff Inflammation...
Items per page:
1 - 10 of 12
BioCentury | Aug 9, 2019
Clinical News

Aug. 9 Clinical Quick Takes: Lexicon's one-year Zynquista follow-up; plus 89bio and TopiVert

...Standing Out in the NASH Crowd" ). TopiVert fails Phase IIb/III dry eye disease study TopiVert...
...SGLT2 - Sodium-glucose cotransporter 2 Sandi Wong, Staff Writer BIO89-100 (TEV-47948) TOP1630 Zynquista, sotagliflozin (SAR439954, lx4211 tablet) 89Bio Ltd. Lexicon Pharmaceuticals Inc. TopiVert Ltd. Non-alcoholic...
BioCentury | Nov 28, 2018
Company News

Management tracks: Abeona, INKEF, Incyte

...COO. Staples was CBO at Artios Pharma Ltd. (Cambridge, U.K.) as well as CBO at TopiVert Ltd....
BioCentury | Mar 10, 2017
Clinical News

TOP1630: Ph I/IIa started

...TopiVert began a U.S. Phase I/IIa trial to evaluate topical TOP1630. TopiVert Ltd. , London, U.K. Product...
...Treat dry eye syndrome Endpoint: Safety Status: Phase I/IIa started Milestone: Phase I/IIa data (2H17) Nora Weintraub TOP1630 TopiVert Ltd....
BioCentury | Oct 17, 2016
Clinical News

rectal TOP1288: Phase IIa started

...once daily for 4 weeks in about 60 patients with moderate to severe disease activity. TopiVert...
...which Johnson & Johnson acquired (see BioCentury, June 7, 2010 & Dec. 12, 2011). TopiVert Ltd....
BioCentury | Mar 28, 2016
Clinical News

TOP1288: Phase I data

...days. Data were presented at the European Crohn’s and Colitis Organization meeting in Amsterdam. Mid-year, TopiVert...
...company also plans to start a Phase I trial evaluating an oral formulation of TOP1288. TopiVert...
...RespiVert Ltd. , which J&J acquired (see BioCentury, June 7, 2010 & Dec. 12, 2011). TopiVert Ltd....
BioCentury | May 25, 2015
Clinical News

TOP1288: Phase I started

...and multiple ascending doses of rectal TOP1288 in healthy volunteers and multiple doses in patients. TopiVert...
...which Johnson & Johnson acquired (see BioCentury, June 7, 2010 & Dec. 12, 2011). TopiVert Ltd....
BioCentury | Jan 16, 2014
Strategy

Biotech kibbutz

...Center Bioceros B.V. Cancer mAb against an undisclosed immune checkpoint regulator to enhance antitumor immunity TopiVert Ltd....
BioCentury | Jan 6, 2014
Financial News

TopiVert completes venture financing

...million) Investors: NeoMed; SV Life Sciences; Imperial Innovations Group; Johnson & Johnson Development Corp. Note: TopiVert...
BioCentury | Dec 12, 2011
Company News

TopiVert, J&J deal

...kinase inhibitors using IP from RespiVert, which was acquired by Johnson & Johnson in 2010. TopiVert...
...inflammatory diseases, while RespiVert will have exclusive rights for other indications. Details were not disclosed. TopiVert Ltd....
BioCentury | Dec 12, 2011
Company News

TopiVert board of directors update

TopiVert Ltd. , London, U.K. Business: Inflammation Appointed: Maina Bhaman, director of Healthcare Investments at Imperial Innovations Group plc WIR Staff Inflammation...
Items per page:
1 - 10 of 12